CNS Pharmaceuticals Inc (CNSP)

CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" SegmentJune 8, 2026 9:15 AM
ACCESS NewswireAccess the segment hereHOUSTON, TX / ACCESS Newswire / June 8, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment.Steve O'Loughlin, Chief Financial Officer of CNS Pharmaceuticals, discussed the Company's recently completed oversubscribed $22.5 million financing in the virtual segment, addressing the factors that enabled the successful capital raise following its strategic reset and acquisition-focused transformation. The conversation explored investor reception to the Company's evolving strategy, the significance of participation from leading healthcare-focused institutional investors and how the strengthened balance sheet enhances CNS Pharmaceuticals' ability to pursue potential transformational opportunities. Mr. O'Loughlin also discussed the importance of institutional support and the Company's long-term vision for creating shareholder value as it advances its next phase of growth.The Virtual Investor "What This Means" segment is available for on-demand viewing here.About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.Forward-Looking Statements
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the anticipated use of proceeds from the Company's recent $22.5 million financing, the Company's ability to identify and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and key milestones related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.CONTACTS:Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.comBusiness Development Contact
CNS Pharmaceuticals, Inc.
Dylan Wenke, Chief Business Officer
dwenke@cnspharma.comSOURCE: CNS Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment

+ 300% 

CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement FinancingMay 4, 2026 7:00 AM
ACCESS NewswireThe private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare PartnersProceeds expected to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategyHOUSTON, TX / ACCESS Newswire / May 4, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, announced today that it has entered into securities purchase agreements for a private placement financing that is expected to result in gross proceeds of approximately $22.5 million to the Company, before placement agent fees and offering expenses.The private placement includes participation from institutional healthcare investors, including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners.Pursuant to the terms of the securities purchase agreements, CNS is selling an aggregate of (i) 650,000 shares of its common stock ("Common Stock") at a purchase price of $2.30 per share and (ii) pre-funded warrants to purchase 9,143,479 shares of Common Stock at a purchase price of $2.299 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share. The private placement is expected to close on or about May 5, 2026, subject to satisfaction of customary closing conditions.CNS intends to use the net proceeds from this private placement, together with existing cash, to identify, acquire, and advance differentiated assets with clear development and regulatory pathways that have clear inflection catalysts and the potential for near-term value creation, as well as for working capital and general corporate purposes. These objectives underpin the Company's new corporate strategy announced on March 11, 2026."With the proceeds from this financing, the Company is now in a strong position to execute on our recently announced corporate strategy and capitalize on opportunities created by the dynamic biotech environment over the last several years," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. "We are grateful for the strong support from leading healthcare investors in this oversubscribed financing, which we believe validates our new strategy and the strength of our team. We expect that the proceeds from the private placement will help us acquire assets with clear development pathways with identifiable near-term catalysts, and with the potential to deliver meaningful value to patients and shareholders."In parallel, CNS is in active discussions to out-license its legacy glioblastoma multiforme programs, Berubicin and TPI-287, allowing the Company to focus its resources on advancing a new acquisition-driven pipeline.A.G.P./Alliance Global Partners acted as the sole placement agent for the transaction.The offer and sale of the foregoing securities will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder. Accordingly, the securities issued in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company intends to file a registration statement with the Securities and Exchange Commission ("SEC") for the resale of the securities issued in the private placement.This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.About CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.Forward-Looking StatementsSome of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the expected gross proceeds and closing of the private placement, the Company's intended use of proceeds from the private placement together with existing cash, the Company's pipeline prioritization and strategic development, the anticipated contributions of the new management team to the Company's growth, expectations regarding clinical development and regulatory strategy, the Company's ability to deliver meaningful value to patients and shareholders, and the Company's plans to explore out-licensing or strategic sales of legacy assets. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.CONTACTS:Investor Relations ContactJTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.comBusiness Development ContactCNS Pharmaceuticals, Inc.
Dylan Wenke, Chief Business Officer
dwenke@cnspharma.comSOURCE: CNS Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing

$CNSP Huge News out: CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners

Proceeds expected to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned with its recently announced corporate strategy

HOUSTON, TX / ACCESS Newswire / May 4, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, announced today that it has entered into securities purchase agreements for a private placement financing that is expected to result in gross proceeds of approximately $22.5 million to the Company, before placement agent fees and offering expenses.

The private placement includes participation from institutional healthcare investors, including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners.

Pursuant to the terms of the securities purchase agreements, CNS is selling an aggregate of (i) 650,000 shares of its common stock ("Common Stock") at a purchase price of $2.30 per share and (ii) pre-funded warrants to purchase 9,143,479 shares of Common Stock at a purchase price of $2.299 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share. The private placement is expected to close on or about May 5, 2026, subject to satisfaction of customary closing conditions.

CNS intends to use the net proceeds from this private placement, together with existing cash, to identify, acquire, and advance differentiated assets with clear development and regulatory pathways that have clear inflection catalysts and the potential for near-term value creation, as well as for working capital and general corporate purposes. These objectives underpin the Company's new corporate strategy announced on March 11, 2026.

"With the proceeds from this financing, the Company is now in a strong position to execute on our recently announced corporate strategy and capitalize on opportunities created by the dynamic biotech environment over the last several years," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. "We are grateful for the strong support from leading healthcare investors in this oversubscribed financing, which we believe validates our new strategy and the strength of our team. We expect that the proceeds from the private placement will help us acquire assets with clear development pathways with identifiable near-term catalysts, and with the potential to deliver meaningful value to patients and shareholders."

In parallel, CNS is in active discussions to out-license its legacy glioblastoma multiforme programs, Berubicin and TPI-287, allowing the Company to focus its resources on advancing a new acquisition-driven pipeline.

A.G.P./Alliance Global Partners acted as the sole placement agent for the transaction.

The offer and sale of the foregoing securities will be made in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder. Accordingly, the securities issued in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company intends to file a registration statement with the Securities and Exchange Commission ("SEC") for the resale of the securities issued in the private placement.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.

For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the expected gross proceeds and closing of the private placement, the Company's intended use of proceeds from the private placement together with existing cash, the Company's pipeline prioritization and strategic development, the anticipated contributions of the new management team to the Company's growth, expectations regarding clinical development and regulatory strategy, the Company's ability to deliver meaningful value to patients and shareholders, and the Company's plans to explore out-licensing or strategic sales of legacy assets. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

CONTACTS:

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com

Business Development Contact

CNS Pharmaceuticals, Inc.
Dylan Wenke, Chief Business Officer
dwenke@cnspharma.com

SOURCE: CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology PipelineMarch 11, 2026 8:35 AM
ACCESS NewswireNewly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing marketsStrategic transformation driven by a comprehensive data analysis will enable new executive team to leverage decades of experience in these therapeutic areasCompany pivoting from a singular focus on glioblastoma and will explore out-licensing of legacy assets berubicin and TPI 287HOUSTON, TX / ACCESS Newswire / March 11, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (the "Company"), a biotechnology company focused on building a pipeline of innovative therapies in high-value neurology and oncology markets, today announced that it has launched a new corporate growth strategy designed to build a high-value pipeline in neurology and oncology. The strategy is being led by the newly formed executive team with deep experience across neurology, oncology and rare disease drug development. The team is driving a disciplined, data-driven approach to identify, acquire and advance differentiated therapeutic programs capable of delivering meaningful clinical and commercial value.CNS Pharmaceuticals conducted an independent, rigorous evaluation of its existing pipeline, development priorities and broader market opportunities as part of a comprehensive strategic review. The process incorporated clinical probability-of-success modeling, competitive landscape assessments, regulatory pathway evaluations and risk-adjusted return analyses. The review was carried out in collaboration with external strategic advisors to ensure a disciplined, scientifically grounded and commercially focused path forward.Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, commented, "We have made impactful progress in a very short period of time and are expecting 2026 to be a year of transformation and execution for CNS Pharmaceuticals. In parallel to a hand-picked, newly formed executive team, we immediately engaged a preeminent consulting firm and have now completed a robust and highly analytical review of our pipeline, development priorities and long-term positioning. We believe CNS Pharmaceuticals is uniquely positioned to leverage the deep expertise of our leadership team and a disciplined approach to capital allocation to build a next-generation biotechnology company focused on high-value opportunities in neurology and oncology."Based on the outcome of this review, the Company is moving towards a defined strategic focus on acquiring or in-licensing preclinical and clinical-stage assets in the therapeutic areas of neurology and oncology. CNS Pharmaceuticals intends to prioritize programs with strong biological rationale, differentiated mechanisms of action, clearly defined development and regulatory pathways and compelling clinical and commercial potential. Particular emphasis will be placed on assets with defined value inflection points and those addressing areas of significant unmet medical need, positioning the Company's pipeline for long-term growth and value creation.Neurology and oncology remain two of the most active and rapidly advancing sectors in biotechnology, supported by large and growing global markets, significant scientific innovation and well-established regulatory frameworks that can accelerate development timelines.Mr. Levin added, "Strategic transformations are a common and often successful approach in biotechnology. With the right leadership experience and a disciplined, data-driven strategy, companies can transform their pipelines and create substantial value. We believe CNS Pharmaceuticals is now prepared to follow this model as we identify, secure and advance differentiated neurology and oncology assets."As part of the strategic review, CNS Pharmaceuticals also evaluated its legacy programs. While scientifically valuable, TPI 287 and berubicin do not align with the Company's forward-looking growth strategy. CNS Pharmaceuticals plans to prepare comprehensive partnering packages to explore potential out-licensing of these assets, enabling the Company to concentrate its resources on advancing a new acquisition-driven pipeline.About CNS Pharmaceuticals, Inc.CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases in neurology and oncology. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS Pharmaceuticals is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.Forward-Looking StatementsSome of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's pipeline prioritization and strategic development, the anticipated contributions of the new management team to the Company's growth, expectations regarding clinical development and regulatory strategy, and the Company's plans to explore out-licensing or strategic sales of legacy assets. These statements relate to future events, future expectations, plans and prospects. Although CNS Pharmaceuticals believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS Pharmaceuticals has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS Pharmaceuticals' most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS Pharmaceuticals undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.CONTACTS:Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.comBusiness Development Contact
CNS Pharmaceuticals, Inc.
Dylan Wenke, Chief Business Officer
dwenke@cnspharma.comSOURCE: CNS Pharmaceuticals, Inc.View the original press release on ACCESS NewswireOriginal: CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

What a bad purchase. Should of dumped it at $2.10 Been a sick week of watching this company go bankrupt

Any chance for a big run soon. Need some help from cnsp

CNSP.............................................................p/m

Hanging on for dear life. 

CNSP under $2

CNSP, new 52 week low

CNSP, new 52 week low

It collapsed $weet$$ My pimp$$ got the cure to cancer RNAZ

CNSP new 52 week low

CNSP TURNING INTO MONSTER

thin thin thin

CNSP MINI POST SPLIT BIO BEAST

CNSP 4 DOLLA BREAK

CNSP HERE COMES 4.00

CNSP 4 BUCKS UP STREAM

CNSP BLOWING UP

CNSP POST SPLIT BIO BEAST

somethings up added

You mean that vague feeling like "hyping" or "blowing wind?"

I see $20 very soon - crazy feeling like a premonition

Looking good

CNSP POST SPLIT BOTTOM

CNSP new 52 week low

CNSP POST SPLIT POPPA

Can you believe this shit? $1,195.00 52 WK high $2.74 52 WK low. Post split adjusted.

CNSP, new 52 week low

People are dumping like there is no tomorrow! It is now down .40,

Maybe in time, maybe in time, but for now few seem to be impressed with CNS. I will wait it out though.

$25 Price Target @ https://stockanalysis.com/stocks/cnsp/

CNSP, new 52/week low

Even that did not work. Disaster after disaster. What a piece of shit CNSP turned out to be.

it will rip tomorrow after a 1 for 50 r/s.

Didn't break .2 but it broke .1 on the downside. Hype doesn't work.

Let’s break 0.2 today!!!!!

Agreed! It’s time to rip today and tomorrow!!!!

Im in lets go.

DILUTION THEN RS

Looks great.

See you above 0.2 soon!!!!!

$CNSP Just filed this Presentation in an 8-k Filing. Check it out on the Link below , ( I always provide links) check out the slide with Management and Past Bio experience , plus PIPELINE Products. Looking good
https://www.sec.gov/ix?doc=/Archives/edgar/data/1729427/000168316825000077/cns_8k.htm

Are there any shareholders on this board that actually want to discuss Berubicin and company potential.

LSEG maintains a current price target of $2.25 for CNSP
Data from Schwab research.

Number of Shares Short 3.63M
When do the shorts have to settle the shorts?

Flip at .16 + 50% most however .20 still possible on volume 

CNSP................................https://stockcharts.com/h-sc/ui?s=CNSP&p=W&b=5&g=0&id=p86431144783